Phase III Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine: A Double-blind, Randomized and Controlled Clinical Trial With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults, and Elderly

Trial Profile

Phase III Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine: A Double-blind, Randomized and Controlled Clinical Trial With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults, and Elderly

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Pneumococcal 23 valent vaccine Sinovac Biotech (Primary)
  • Indications Pneumococcal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Sinovac Biotech
  • Most Recent Events

    • 12 Oct 2017 According to a Sinovac Biotech media release, the company has filed the NDA for its 23-valent Pneumococcal Polysaccharide Vaccine to the CFDA on 3 August 2017. This vaccine is used to prevent streptococcus pneumoniae (pneumococcus) infections such as pneumonia and septicemia among adults aged 65 or older, adults with serious long-term health problems, smokers, and children older than two years with serious long-term health problems.
    • 01 May 2017 Status changed from active, no longer recruiting to completed.
    • 15 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top